David Kirn Sells 12,930 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) CEO David Kirn sold 12,930 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $23.10, for a total transaction of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at $24,466,434.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $20.93 on Friday. The business has a 50-day moving average of $24.51 and a 200-day moving average of $24.61. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -8.58 and a beta of 2.89. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.07. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative return on equity of 26.75% and a negative net margin of 436.30%. On average, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Trexquant Investment LP bought a new position in shares of 4D Molecular Therapeutics in the third quarter valued at about $566,000. RA Capital Management L.P. lifted its holdings in 4D Molecular Therapeutics by 35.6% during the 3rd quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after purchasing an additional 1,093,680 shares during the last quarter. Wellington Management Group LLP boosted its stake in 4D Molecular Therapeutics by 2.2% in the 3rd quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock valued at $2,199,000 after purchasing an additional 3,638 shares during the period. SG Americas Securities LLC grew its holdings in 4D Molecular Therapeutics by 119.5% in the 4th quarter. SG Americas Securities LLC now owns 26,899 shares of the company’s stock valued at $545,000 after buying an additional 14,645 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in 4D Molecular Therapeutics by 359.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock worth $100,000 after buying an additional 3,873 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

FDMT has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday. Barclays started coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They set an “overweight” rating for the company. Jefferies Financial Group raised their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, June 7th. Finally, BMO Capital Markets reduced their price objective on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, April 1st. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $45.63.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.